{"id":"mv140","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Gastrointestinal symptoms"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MV140 contains inactivated lysates from four uropathogenic bacteria (Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Morganella morganii) commonly responsible for recurrent UTIs. The vaccine is administered orally and intramuscularly to activate mucosal and systemic immunity, enhancing the body's ability to recognize and eliminate these pathogens before infection establishes.","oneSentence":"MV140 is a polyvalent bacterial lysate vaccine that stimulates innate and adaptive immune responses to prevent recurrent urinary tract infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:19.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of recurrent urinary tract infections in adults"}]},"trialDetails":[{"nctId":"NCT06392282","phase":"","title":"MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Unidade Local de Saúde Santa Maria","startDate":"2023-06-01","conditions":"Urinary Tract Infections","enrollment":104},{"nctId":"NCT04173013","phase":"","title":"Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)","status":"NO_LONGER_AVAILABLE","sponsor":"Impatients N.V. trading as myTomorrows","startDate":"","conditions":"Urinary Tract Infections, Chronic Urinary Tract Infection, Recurrent Urinary Tract Infection","enrollment":""},{"nctId":"NCT02543827","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of MV140","status":"COMPLETED","sponsor":"Inmunotek S.L.","startDate":"2015-11","conditions":"Urinary Tract Infection Bacterial","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MV140","genericName":"MV140","companyName":"Inmunotek S.L.","companyId":"inmunotek-s-l","modality":"Biologic","firstApprovalDate":"","aiSummary":"MV140 is a polyvalent bacterial lysate vaccine that stimulates innate and adaptive immune responses to prevent recurrent urinary tract infections. Used for Prevention of recurrent urinary tract infections in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}